Data protection Impressum

Search Result for 'lonza' :

The latest collaboration complements Vaxcyte’s strategy to commence the initial commercial launch of VAX-24, a vaccine that targets the prevention of invasive pneumococcal disease (IPD).

Lonza expands to manufacture Vaxcyte’s pneumococcal conjugate vaccine

Lonza and US clinical-stage vaccine innovation company Vaxcyte have announced an expansion in their partnership to establish a global commercial…

CDMOs play a crucial role in the pharmaceutical sector, serving as key partners in the drug development and production process.

Siegfried and Lonza secure top positions in global pharmaceutical outsourcing rankings

Valais-based pharmaceutical companies Lonza and Siegfried have been recognized among the leading players in the global outsourcing landscape, with respective…

Lonza continues to fortify its position in ADC production, expanding collaboration and infrastructure to enhance its acclaimed Ibex Dedicate Biopark.

Lonza further extends its ADC manufacturing capabilities in Visp

Lonza amplifies ADC production via a robust extension in bioconjugation capacity at its Ibex Dedicate Biopark in Visp, which set…

Lonza boosts next-generation anticancer drugs with CHF 97 million investment in Visp

Pharma giant Lonza is enhancing its capabilities in the development of novel cancer treatments through an investment of over CHF…

Lonza uses virtual reality to train and attract talented workers

Lonza's Visp site has developed a training tool that uses virtual reality. To this day, more than 250 people have…

The partnership between Lonza and the HES-SO Valais-Wallis is yielding results

The partnership between Lonza and the HES-SO Valais-Wallis aimed at building joint competencies in the field of education and research…

Lonza invests CHF 650 million in a new large-scale production facility in Visp

Biopharmaceutical giant Lonza has announced expansion plans for next-generation mammalian manufacturing facilities on its Visp site. With an investment of…

Lonza invests CHF 200 million in a new production facility in Visp

Biopharmaceutical company Lonza will build a new manufacturing facility dedicated to small molecules at its site in Visp. The new…

Lonza to create 1,200 new jobs at its Covid-19 vaccine production site in Visp

Biopharmaceutical giant Lonza has announced the creation of 1,200 new jobs for the manufacturing of Moderna’s Covid-19 vaccine on its…

Biopharmaceutical giant Lonza to build two new production lines and create 200 new jobs in Valais

Following a long-term strategic agreement in the field of bioconjugates with a global biopharmaceutical company, Lonza will build two new…

1 2 3